Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca²⁺ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.

ABSTRACT: Several new therapeutic options emerged recently to treat metastatic melanoma; however, the high frequency of intrinsic and acquired resistance among patients shows a need for new therapeutic options. Previously, we identified the plasma membrane Ca²⁺ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas and found that mutant BRAF inhibition increased the expression of the pump, which then inhibited the migratory and metastatic capability of the cells. Earlier it was also demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and valproic acid, either alone, or in combination with

SUBMITTER: Hegedus L 

PROVIDER: S-EPMC5442207 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature